Simbiya is an antidepressant, with active ingredient - duloksetin. Indications - treatment of big depressive disorder, treatment of diabetic, peripheral, neuropatichesky pain, treatment of a generalized anxiety disorder.

Structure

• 1 capsule supports a duloksetin of a hydrochloride of 33.7 mg that is equivalent a duloksetina of 30 mg;
• excipients: spherical sugar, hydroxypropyl cellulose, gipromelloza, gipromelloza phthalate (NR-55), triethyl citrate, talc;
• a capsule cover (for a dosage of 30 mg) the titan dioxide (E 171), diamond blue FCF (E 133), a gipromelloza (E 464), ferrous oxide black (E172).

Contraindication

Contraindication for use of medicine is the hypersensitivity to a duloksetin or to any of medicament excipients.

cannot appoint Simbiya the patient with unstable hypertensia as it can provoke hypertensive crisis.

cannot appoint Medicine the patient with an end-stage of a renal failure (clearance of creatinine - to 30 ml/min.).

with liver diseases as it can cause a liver failure.

Route of administration

Big depressive disorder.

Initial and recommended maintenance dose makes 60 mg, 1 time a day, apply irrespective of meal. The dosage more than 60 mg, 1 time a day to maximum of 120 mg a day were estimated in terms of safety. However there are no clinical data that for patients who do not react to the initial recommended dose there will be effective an increase in a dose.

in 2 - 4 weeks of treatment.

. At patients who react on duloksetin and at the anamnesis of repeated episodes of a great depression, it is necessary to consider further long-term treatment in a dose of 60 - 120 mg a day.

Feature of use

to Patients with high risk of a suicide during treatment needs to be under strict observation as before considerable remission the possibility of attempt of a suicide is not excluded.

Possibility of use of a duloksetin of a hydrochloride it was not studied at patients aged up to 18 years therefore it is not intended for use to this age group.

by

only under a condition if the expected effect exceeds risk.

Children

Clinical trials on use of a duloksetin to children (aged up to 18 years) were not conducted by

therefore it is applied in pediatric practice.

Drivers

Drug can show sedation and dizziness. During treatment the patients should abstain from potentially dangerous types of activity requiring special attention and speed of psychomotor reactions.

Overdose

overdose Symptoms (mainly at a combination with other medicines) included drowsiness, a coma, a serotoninovy syndrome, spasms, epileptic seizures, vomiting and tachycardia.

Side effects

from an organ of sight: indistinct image, mydriasis, disorders of vision, xerophthalmus.

from organs of hearing and a vestibular mechanism: a ring in ears, dizziness, ear pain.

from the respiratory system, bodies of a thorax and mediastinum: yawning, oropharyngeal pain, feeling of compression in a throat, nasal bleeding.

from digestive tract: constipation, diarrhea, vomiting, dyspepsia, meteorism, abdominal pain.

to Store

in original packing at a temperature not above 25 °C.

to Store

out of children's reach.